Table 3.
Cases given AVT No. of patients (%) |
Cases never given No. of patients (%) |
p | |
---|---|---|---|
Total number of patients | N=26 | N=40 | |
Demographics | |||
Age, years [median (IQR)] | 58 (54 - 65) | 59 (53 - 63) | 0.89 |
Gender, male | 21/26 (81) | 26/40 (65) | 0.16 |
Race, white | 19/26 (73) | 25/39 (64) | 0.44 |
DLBCL characteristics | |||
De novo DLBCL | 21/26 (81) | 28/40 (70) | 0.32 |
Immunohistochemistry, GCB | 11/19 (58) | 16/29 (55) | 0.85 |
Ann Arbor, stage 3-4 | 19/25 (76) | 33/40 (83) | 0.52 |
Extranodal involvement | 20/26 (77) | 31/40 (78) | 0.95 |
Presence of B symptoms | 8/26 (31) | 12/37 (32) | 0.88 |
ECOG score, 2-4 | 7/23 (30) | 10/32 (31) | 0.94 |
IPI score, high risk | 7/19 (37) | 5/31 (16) | 0.17 |
Bone marrow biopsy, positive | 8/26 (31) | 15/38 (40) | 0.47 |
LDH level, U/L [median (IQR)] | 631 (522 - 943) | 657 (499 - 1075) | 0.66 |
Infectious characteristics | |||
HCV genotype 1 | 13/21 (62) | 27/34 (79) | 0.15 |
HbsAg, positive | 0 | 2/40 (3) | 0.51 |
HbcAb, positive | 12/26 (46) | 18/40 (45) | 0.92 |
HBV DNA, detected | 2/10 (20) | 2/17 (12) | 0.61 |
Hepatic characteristics | |||
Cirrhosis | 5/26 (19) | 10/40 (25) | 0.58 |
Child Pugh score A | 3/5 (60) | 4/10 (40) | 0.61 |
Portal hypertension | 4/5 (80) | 9/10 (90) | 0.90 |
METAVIR, stage 3-4 | 9/16 (56) | 2/10 (20) | 0.10 |
Oncologic treatment | |||
First line chemotherapy, RCHOP | 20/26 (77) | 25/29 (86) | 0.27 |
HCT | 6/26 (23) | 7/38 (18) | 0.64 |
Radiotherapy | 8/26 (31) | 11/38 (29) | 0.87 |
Received further chemotherapy | 12/26 (46) | 16/37 (43) | 0.81 |
Second line chemotherapy, RICE | 8/13 (62) | 10/15 (67) | >0.99 |
Oncologic outcomes | |||
PFS, months [median (IQR)] | 27 (7 - 45) | 10 (4 - 42) | 0.18 |
DFS, months [median (IQR)] | 24 (3 - 41) | 6 (0 - 34) | 0.10 |
OS, months [median (IQR)] | 39 (26 - 56) | 16 (6 - 41) | 0.02 |
AVT indicates antiviral therapy; IQR, interquartile range; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; HCV, hepatitis C virus; HbsAg, hepatitis b surface antigen; HbcAb, hepatitis b core antibody; HBV, hepatitis B virus; R-CHOP, rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone; HCT, hematopoietic stem cell transplantation; R-ICE, rituximab-ifosfamide, carboplatin, and etoposide; PFS, progression free survival; DFS, disease free survival; and OS, overall survival.